Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S2W-21267 · Session 2

Further to the answer to question S2W-20285 by Mr Andy Kerr on 10 November 2005, why NHS Quality Improvement Scotland is awaiting the final…

Answered Asked by Alex Neil SNP Lodged 30 Nov 2005

The question

To ask the Scottish Executive, further to the answer to question S2W-20285 by Mr Andy Kerr on 10 November 2005, why NHS Quality Improvement Scotland is awaiting the final recommendation of the National Institute for Clinical Excellence in relation to its consultation document, Alzheimer’s disease – donepezil, rivastigmine, galantamine and memantine, when NHS Quality Improvement Scotland is responsible for making recommendations in respect of the use of these drugs within the NHS in Scotland.

The answer

Answered by Andy Kerr on 12 Dec 2005 · 12 days after it was lodged, on time

NHS Quality Improvement Scotland (NHS QIS) has published comments on all NICE appraisals since May 2001. It does not re-assess the evidence used by NICE to avoid duplication of effort and to ensure public resources are used effectively and efficiently. NHS QIS considers possible differences in the application of appraisals for Scotland based on four criteria:
Principles and values of NHSScotland
Epidemiology (frequency, distribution and stage at presentation)
Structure and provision of services in Scotland
Other implications for NHSScotland, including rural issues, predicted uptake or existing advice from the Scottish Medicines Consortium.
NHS QIS involves a small number of experts in this process, and this has allowed it to make decisions about the validity of NICE appraisals for Scotland prior to the publication of the appraisal by NICE. Consequently it issues its comments to NHS board chief executives on the same day as NICE publishes its appraisal (usually on the fourth Wednesday of each month).

In the Official Report

No contribution in the Official Report cites S2W-21267 by reference.